Equities

JCR Pharmaceuticals Co Ltd

JCR Pharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)654.00
  • Today's Change-2.00 / -0.30%
  • Shares traded57.30k
  • 1 Year change-46.04%
  • Beta0.4664
Data delayed at least 20 minutes, as of Nov 13 2024 00:48 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform2
Hold5
Sell0
Strong Sell0

Share price forecast in JPY

The 8 analysts offering 12 month price targets for JCR Pharmaceuticals Co Ltd have a median target of 665.00, with a high estimate of 2,000.00 and a low estimate of 600.00. The median estimate represents a 1.37% increase from the last price of 656.00.
High204.9%2,000.00
Med1.4%665.00
Low-8.5%600.00

Dividends in JPY

In 2024, JCR Pharmaceuticals Co Ltd reported a dividend of 20.00 JPY, equaling last years dividend. The 7 analysts covering the company expect dividends of 20.00 JPY for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in JPY

On Oct 30, 2024, JCR Pharmaceuticals Co Ltd reported 2nd quarter 2025 losses of -7.14 per share.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate-42.09%
JCR Pharmaceuticals Co Ltd reported annual 2024 earnings of 44.13 per share on May 10, 2024.
Average growth rate+59.58%
More ▼

Revenue history & estimates in JPY

JCR Pharmaceuticals Co., Ltd. had 2nd quarter 2025 revenues of 8.51m. This missed the 11.30m estimate of the one analyst following the company. This was 21.24% below the prior year's 2nd quarter results.
Average growth rate-9.88%
JCR Pharmaceuticals Co., Ltd. had revenues for the full year 2024 of 42.87m. This was 24.83% above the prior year's results.
Average growth rate+20.81%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.